Androgen replacement therapy in the hypogonadal ageing man

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 6, 2003, Pages 911-918

  Morales, Alvaro ^a  

^a KINGSTON GENERAL HOSPITAL   (Canada)

Author keywords

Ageing; Androgen therapy; Hypogonadism

Indexed keywords

ANDROGEN; ANDROSTENEDIONE; FLUOXYMESTERONE; GROWTH HORMONE; LONG ACTING DRUG; MELATONIN; METHYLTESTOSTERONE; PRASTERONE; PRASTERONE SULFATE; SEX HORMONE BINDING PROTEIN; SOMATOMEDIN C; TESTOSTERONE; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE; TESTOSTERONE ESTER; TESTOSTERONE PROPIONATE; TESTOSTERONE UNDECANOATE;

ADULT; AGED; AGING; BIOCHEMISTRY; BREAST TENDERNESS; CLIMACTERIUM; CLINICAL FEATURE; CORRELATION FUNCTION; DEPOT; DERMATITIS; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG COST; DRUG DOSAGE FORM; DRUG EFFICACY; GONAD FUNCTION; GYNECOMASTIA; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; LIVER CELL CARCINOMA; LIVER CYST; LIVER TOXICITY; MALE; MALE GENITAL SYSTEM; OBSTRUCTIVE JAUNDICE; PATIENT MONITORING; REVIEW; TARGET ORGAN; TRANSDERMAL PATCH;

AGING; ANDROGENS; CLIMACTERIC; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE;

EID: 0038009100     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.6.911     Document Type: Review

References (50)

1. KAUFMAN JM: Hypothalamic-pituitary-gonadal function in aging men. Aging Male (1999) 2:157-165.
2. ROMMERTS FFG: Tcstosterone an overview of biosynthesis, transport, metabolism and non-genomic actions. In: Testosterone: action, deficiency substitution. Nieschlag E, Behre HM (Eds), Springer, Berlin, Germany (1998):1-26.
3. STERNBAH H: Age-associated testosterone decline in men: clinical uses for psychiatry. Am. J. Psychiatry (1998) 155:1310-1318.
4. BARRETT-CONNOR E, VON MUHLEN DG, KRITZ-SILVERSTEIN D: Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo Study. J. Clin. Endocrinol. Metab. (1999) 84:573-577.
5. BAGATELL CJ, BREMNER WJ: Drug therapy: androgens in men - uses and abuses. N. Engl. J. Med. (1996) 334(11):707-714.
6. RIGGS BL, KHOSLA S, MELTON LJ 3rd. Sex steroids and the construction and conservation of the adult skeleton. Endocr. Rev. (2002) 23(3):279-302.
7. CUNDY T, AMES R, HORNE A et al.: A randomized controlled trial of estrogen replacement therapy in long-term users of depot medroxyprogesterne acetate. J. Clin. Endocrinol. Metab. (2003) 88:78-81.
8. LEDER BZ, LEBLANC KM, SCHOENFELD DA et al.: Differential effects of androgens and estrogens on bone turnover in normal men. J. Clin. Endocrinol. Metab. (2003) 88:204-210.
9. BAULIEU E-E: Dehydroepiandrosterone (DHEA): a fountain of youth? J. Clin. Endocrinol. Metab. (1996) 81(9):3147-3151.
10. VERMEULEN A: Dehydroepiandrosterone sulfate and aging. Ann. NY Acad. Sci. (1995) 774:121-127.
11. LEGRAIN S, MASSIEN AC, LAHLOU N et al.: DHEA replacement administration: pharmacokinetic and pharmacodynamic studies in healthy elderly subjects. J. Endocrinol. Metab. (2000) 85:3208-3217.
12. ARLT W, CALLIES, F, KOEHLER I et al.: DHEA Supplementation in healthy men with an age related decline of DHEA secretion. J. Clin. Endocrinol. Metab. (2001) 86:4686-4692.
13. VELDHUIS JD: Elements in the pathophysiology of diminished growth hormone (GH) secretion in aging humans. Endocrine (1997) 7:41-48.
14. KLEINBERG DL, MELMED S: The adult GH deficiency syndrome: signs, symptoms and diagnosis. The Endocrinologist (1998) 8:8(S).
15. MOLITCH ME: Editorial: diagnosis of GH deficiency in adults - how good do the criteria need to be? J. Clin. Endocrinol. Metab. (2002) 87:473-476.
16. BLOCK GJ, DE BOER H, GOOREN LJG, VAN DER VEEN EA: Growth hormone substitution in adult growth-hormone deficient men augments androgen effect on the skin. Clin. Endocrinol. (1997) 47:29-34.
17. Consensus. Critical evaluation of the safety of recombinant human growth hormone administration: statement from the Growth Hormone Research Society. J. Clin. Endocrinol. Metab. (2001) 86:1868-1870.
18. LIU RY, ZHOU JN, VAN HEERIKHUIZE J, HOFMAN MA, SWAAB DF: Decreased melatonin levels in post-mortem cerebro-spinal fluid in relation to ageing, Alzheimer's disease and apoliprotein E-ε4/4 genotype. J. Clin. Endocrinol. Metab. (1999) 84:323-327.
19. OLCESE J: Melatonin and the aging male. Aging Male (1998) 1(Suppl. 1):9.
20. SEWERYNEK E, MELCHIORRI D, REITER RJ, ORTIZ GG, LEWINSKI A: Lipopolysaccharide-induced hepatotoxicity is inhibited by the antioxidant melatonin. Eur. J. Pharmacol. (1995) 293:327-334.
21. MAESTRONI GJ: The immunoneuroendocrine role of melatonin. J. Pineal Res. (1993) 14(1):1-10.
22. BLACKMAN MR. Age-related alterations in sleep quality and neuroendocrine function. JAMA (2000) 284:879-881.
23. WURTMAN RJ: Editorial: age related decreases in melatonin secretion - clinical consequences. J. Clin. Endocrinol. Metab. (2000) 85(6):2135-2136.
24. OLCESE J: Cellular and molecular mechanisms mediating melatonin action. Aging Male (1998) 1:113-128.
25. GOOREN LJG: The age-related decline of androgen levels in men: clinically significant? Br. J. Urol. (1996) 78:763-768.
26. MORALES A, LUNENFELD B: Androgen replacement therapy in aging male with secondary hypogonadism. Aging Male (2001) 4:151-157.
27. MORLEY JE: Clinical diagnosis of age-related testosterone deficiency. Aging Male (2000) 3(Suppl. 1):195.
28. HEINEMAN LAJ, SAAD F, THIELE K et al.: The aging male's symptom rating scale: cultural and linguistic validation into english. Aging Male (2001) 4:14-22.
29. VERMEULEN A, KAUFMAN JM: Aging of the hypothalamo-pituitary-testicular axis in men. Hormone Res. (1995) 43:25-32.
30. MORLEY JE: Andropause, testosterone treatment and quality of life in aging men. Cleveland Gin. J. Med. (2000) 67:880-886.
31. PLYMATE SR, TENOVER JS, BREMMER WJ: Circadian variation in testosterone, sex hormone binding globulin and calculated non-sex hormone binding globulin bound testosterone in healthy young men and elderly men. J. Androl. (1989) 10:366-371.
32. MORLEY J, PING P, PERRY HM: Evaluation of assays available to measure free testosterone. Metabolism (2002) 51:554-559.
33. FINKELSTEIN JS, KILBANSKI A, NEER RM et al.: Increases in bone density during treatment of men with idiopathic hypogonadotrophic hypogonadism. J. Clin. Endocrinol. Metab. (1989) 69:776-782.
34. MORALES A, JOHNSTON B, HEATON JWP, CLARK A: Oral androgens in the treatment of hypogonadal impotent men. J. Urol. (1994) 152:1115-1120.
35. BAGATELL CJ, BREMNER WJ: Androgen and testosterone effects on plasma lipids. Prog. Cardiovasc. Dis. (1995) 38:255-271.
36. GOOREN LJG: A ten year safety study of the oral androgen testosterone undecanoate. Androl. (1994) 15:212-217.
37. SOKOL RZ, PALACIOS A, CAMPFIELD LA: Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. Fertil. Steril. (1982) 37(3):425-430.
38. TENOVER JS: Androgen administration to aging men. Endocrinol. Metab. Clin. N. Am. (1994) 23:877-892.
39. BHASIN S, BREMNER WJ: Emerging issues in androgen replacement therapy. J. Clin. Endocrin. Metab. (1997) 82:3-8.
40. MCCLELLAN KJ, GOA KL: Transdermal testosterone. Drug (1998) 55:253-258.
41. ARVER S, MEIKLE AW, DOBS AS, MAZER NA. Permeation enhanced testosterone transdermal systems in the treatment of male hypogonadism: long term effects. J. Endocrinol. (1996) 148:254-259.
42. DOBBS AS, MEIKLE AW, ARVER S et al.: Pharmacokinetics, efficacy and safety of a permeation-enhanced testosterone transdermal system in comparison with weekly injections of testosterone enanthate for the treatment of hypogonadal men. J. Clin. Endocrinol. Metab. (1999) 84:3469-3478.
43. FINDLAY JC, PLACE V, SNYDER PJ: Treatment of primary hypogonadism in men by the transdermal administration of testosterone. J. Clin. Endocrinol. Metab. (1989) 68:369-373.
44. JORDAN WP, ATKINSON LE: Comparison of the skin irritation potential of two testosterone transdermal systems: an investigational system and a marketed product. Clin. Therapeutics (1998) 20:80-87.
45. SWERDLOFF RS, WANG C, CUNNINGHAM G et al.: Long-term pharmacokinetic of transdermal testosterone gel in hypogonadal men. J. Clin. Endocrinol. Metab. (2000) 85:4500-4510.
46. WANG C, SWERDLOFF RS, IRANMANESH A et al.: Transdermal testosterone gel improves sexual function, mood, muscle strength and body composition parameters in hypogonadal men. J. Clin. Endocrinol. Metab. (2000) 85:2839-2853.
47. KUNELIUS P, LUKKARINEN O, HANNUKSELA ML et al.: The effect of transdermal dehydrotestosterone in the aging male: a prospective, randomized, double blind study. J. Clin. Endocrinol. Metab. (2002) 87:1467-1472.
48. WANG C, SWERDLOFF RS: Should non-aromatizable androgen dehydrotestosterone be considered as an alternative to testosterone in the treatment of the andropause? J. Clin. Endocrinol. Metab. (2002) 87:1462-1466.
49. BEHRE HM, KLEISH S, LEIFKE E, LINK TM, NIESCHLAG E: Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J. Clin. Endocrinol. Metab. (1997) 82:2386-2390.
50. MORALES A, LUNENFELD B: Investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male (2002) 5:74-86.